Biotech leaders sign open letter asking Trump to reconsider rescinding DACA
Following President Trump's decision Tuesday to end the Deferred Action for Childhood Arrivals (DACA) program, a number of biotech leaders signed an open letter asking the president to reverse his decision.
On Tuesday morning, Attorney General Jeff Sessions announced that the program, which provides work permits for young immigrants known as "Dreamers" who entered the country illegally as children, will be phased out in the next six months. In response, more than 50 senior executives at biotechs and research organizations led by Steven Holtzman, CEO of Decibel Therapeutics Inc. (Boston, Mass.), and Jeremy Levin, CEO of Ovid Therapeutics Inc. (NASDAQ:OVID), asked Trump to preserve the DACA program and called on Congress to pass the DREAM Act or similar legislation that would provide permanent protection for Dreamers...